Frecuencia de infección por virus de papiloma humano no asociados a cáncer y distribución de genotipos en población genera

Benites Zapata, Vicente A; Tejada Caminiti, Romina A; Mezones Holguín, Edward M. A.
Lima; Instituto Nacional de Salud; abr. 2013.
No convencional en Español | BRISA | ID: biblio-904868

Documentos relacionados

  1. The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules.
  2. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.
  3. The study protocol of the evaluation for the preventive efficacy of the HPV vaccine for persistent HPV16/18 infection in Japanese adult women: the HAKUOH study.
  4. Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination.
  5. Assessing the reduction of viral infectivity in HPV16/18-positive women after one, two, and three doses of Gardasil-9 (RIFT): Study protocol.
  6. The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules
  7. Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow-up cohort study.
  8. The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age.
  9. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
  10. Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV.